UNSPSC 51351902: Ethynodiol diacetate

This classification denotes a therapeutic progestin with the molecular formula C24H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 62H10A1236, chemically known as 19-norpregn-4-en-20-yne-3,17-diol, diacetate, (3.beta.,17.alpha.)- but generally known as ethynodiol diacetate, which bears US NIH Compound Identifier 3304. European Medicines Agency schedules Etynodiol diacetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02051MIG.

As of Q4 2014, ETHYNODIOL DIACETATE remains the US FDA Preferred Term for this commodity. Ethynodiol diacetate bears US NLM identifiers UMLS ID C0015117 and NCI Concept Code C47525. SMILES: CC(=O)OC1CCC2C3CCC4(C(C3CCC2=C1)CCC4(C#C)OC(=O)C)C.

UNSPSC 51351902 Ethynodiol diacetate, a Commodity code, encompasses the procurement of this specific oral contraceptive pharmaceutical by state and local government health systems, agencies, and facilities. State and local buyers use this code to source individual active pharmaceutical ingredients and finished contraceptive products distributed through cooperative purchasing agreements and direct pharmaceutical supply chains. The issuing bodies soliciting under this code include state health departments, multistate cooperative purchasing alliances, and subordinate local health agencies and institutional buyers within those agreements.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products with a response deadline of March 26, 2026. The MMCAP solicitation covers a broad generic pharmaceutical family that includes ethynodiol diacetate among other drugs, distributed across participating state and local government facilities in Minnesota, Oregon, and other MMCAP member jurisdictions. Vendors must supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), maintain current Good Manufacturing Practices and Drug Supply Chain Security Act compliance, and demonstrate pricing flexibility across multiple net-price formats. The contract term runs two years for new responders with optional extensions, with awarded vendors effective July 1, 2026, and the solicitation applies a weighted evaluation favoring price competitiveness at 75 percent of the score. No specific dollar value or set-aside designations are disclosed in the available documentation.